An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

Diabetes, Obesity and Metabolism

Volumn 13, Issue 5, 2011, Pages 394-407

  Madsbad, S ^a   Kielgast, U ^a   Asmar, M ^b   Deacon, C F ^b   Torekov, S S ^b   Holst, J J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Albiglutide; Antidiabetic drug; CJC 1134 PC; Exenatide once weekly; GLP 1 analogue; GLP 1 receptor agonists; Incretin therapy; LY2189265; Taspoglutide; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ANTIDIABETIC AGENT; BYDUREON; CJC 1134 PC; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; SEMAGLUTIDE; SITAGLIPTIN; TASPOGLUTIDE; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HALF LIFE TIME; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; INJECTION SITE REACTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; REVIEW; VOMITING;

EID: 79953040963     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01357.x     Document Type: Review

References (88)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 1270-1287.
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
4. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
5. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
6. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
7. Adler AI, Shaw EJ, Stokes T, Ruiz F. Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance. BMJ 2009; 338: 1668.
8. Bhattacharyya OK, Estey EA, Cheng AY. Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician 2009; 55: 39-43.
9. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
10. Schernthaner G, Barnett AH, Betteridge DJ et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010; 53: 1258-1269.
11. Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009; 23: 487-498.
12. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008; 11: 491-499.
13. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009; 23: 463-477.
14. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206.
15. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
16. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
17. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 2008; 14: 161-168.
18. Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32 (Suppl 2): S223-231.
19. Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1): E981-E988.
20. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
21. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
22. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
23. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952-957.
24. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131.
25. Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 2003; 19: 141-150.
26. Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67: 935-954.
27. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 2006; 46: 635-641.
28. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405.
29. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.
30. Vilsboll T, Krarup T, Madsbad S, Holst JJ. No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabet Med 2001; 18: 144-149.
31. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
32. Buse JB, Sesti G, Schmidt WE et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33: 1300-1303.
33. Vaag A, Nauck MA, Brandle M et al. Liraglutide, a human GLP-1 analogue, substantially reduces HbA(1c) in subjects with type 2 diabetes, irrespective of HbA(1c) at baseline. Diabetologia 2008; 51: S68-69.
34. Buse J, Montanya E, Sesti G et al. The incidence of antibody formation and the levels of antibodies are lower with liraglutide than exenatide in a head-to-head comparison. Diabetologia 2010; 53(Suppl. 1): S341.
35. Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
36. Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493.
37. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2009; 18: 359-367.
38. Tracy MA, Ward KL, Firouzabadian L et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999; 20: 1057-1062.
39. Buse JB, Drucker DJ, Taylor KL et al. DURATION-1 exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010; 33: 1255-1261.
40. Knudsen LB, Jelsing J, Vrang N, Tang-Christensen M, Raun K. Liraglutide: short lived effect on gastric emptying-long lasting effects on body-weight. Diabetes 2010; 59: A161.
41. Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009; 26: 722-728.
42. Bergenstal RM, Wysham C, MacConell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439.
43. Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
44. Diamant M, Van GL, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
45. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
46. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
47. Pullman J, Blevins TC, Malloy J et al. DURATION-5: exenatide once weekly resulted in significantly greater improvement in glycaemic control than exenatide twice daily in patients with type 2 diabetes. Diabetologia 2010; 53: S336.
48. Linnebjerg H, Seger M, Kothare P, Hunt TC, Mitchell MI. The effect of exenatide on QTc interval in healthy subjects. Diabetes 2009; 58: A161.
49. Sebokova E, Christ AD, Wang H et al. Taspoglutide, an analog of human glucagon-like peptide-1 with enhanced stability and in vivo potency. Endocrinology 2010; 151: 2474-2482.
50. Uhles S, Brecheisen M, Benardeau A et al. Taspoglutide, a novel human once-weekly GLP-1 analogue, improves beta-cell survival in ZDF rats. Diabetes 2010; 59: A148.
51. Pellanda C, Mangold B, Schulte M, Niggli M, Kapitza C. Effect of taspoglutide, a human GLP-1 analog, on insulin secretion in patients (pts) with type 2 diabetes (T2D). Diabetes 2010; 59: A160-A161.
52. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009; 32: 1237-1243.
53. Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study. Diabet Med 2010; 27: 556-562.
54. Kapitza C, Heise T, Klein O et al. BIM51077, a novel GLP-1 analog, achieves sustained improvement in blood glucose control over 28 days of treatment. Diabetes 2006; 55: A119.
55. Raz I, Fonseca V, Kipnes M et al. Taspoglutide, a once-weekly human GLP-1 analog, as monotherapy significantly lowers A1c and body weight in patients with type 2 diabetes (T2D): results from the T-emerge 1 phase 3 trial. Diabetes 2010; 59: A107.
56. Rosenstock J, Balas B, Charbonnel B et al. Superior glycemic control with taspoglutide, a once-weekly human GLP-1 analog, compared with twice daily exenatide in type 2 diabetes (T2DM) inadequately controlled on oral agents: the T-emerge 2 trial. Diabetes 2010; 59: A17.
57. Rosenstock J, Balas B, Charbonnel B et al. Taspoglutide, a once-weekly human GLP-1 analog, improves glucose tolerance and insulin secretion in patients with type 2 diabetes (T2DM): results of a meal tolerance test from T-emerge 2. Diabetes 2010; 59: A196.
58. Bergenstal R, Forti A, Chiasson JL et al. Once weekly taspoglutide, a human GLP-1 analog, is superior to sitagliptin in improving glycemic control and weight loss in patients with type 2 diabetes (T2D): results from the T-emerge 4 trial. Diabetes 2010; 59: A16.
59. Nauck M, Horton E, Andjelkovic M, mpudia-Blasco FJ, Boldrin MN, Balena R. Taspoglutide, a once-weekly human GLP-1 analog, provides comparable glycemic control to insulin glargine, ' with superior weight loss and less hypoglycemia in type 2 diabetes (T2D): a phase 3, open-label trial (T-emerge 5). Diabetes 2010; 59: A16.
60. Hollander P, Bengus M, Barnett A et al. Once-weekly taspoglutide, a human GLP-1 analog, is superior to placebo in improving glycemic control and body weight loss in obese patients with type 2 diabetes (T2D) inadequately controlled with metformin monotherapy: results from the T-emerge 7 trial. Diabetes 2010; 59: A160.
61. Bush MA, Matthews JE, De Boever EH et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009; 11: 498-505.
62. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998; 41: 271-278.
63. Bloom M, Bock J, Duttaroy A et al. Albugon (TM) fusion protein: a long-acting analog of GLP-1 that provides lasting antidiabetic effect in animals. Diabetes 2003; 52: A112.
64. Matthews D, Marre M, Le-Thl TUD, Zdravkovic M, Simo R. Liraglutide, a once-daily human GLP-1 analog, significantly improves beta-cell function in subjects with type 2 diabetes. Diabetes 2008; 57: A150-A151.
65. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009; 32: 1880-1886.
66. GlaxoSmithKline. About the HARMONY type 2 diabetes Medical Research Study. Available from URL: Accessed 14 May 2010.
67. Glaesner W, Vick AM, Millican R et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010; 26: 287-296.
68. Umpierrez G, Blevins T, Rosenstock J, Cheng C, Bastyr E, Anderson J. The effect of LY2189265 (GLP-1 analogue) once weekly on HbA(1c) and beta cell function in uncontrolled type 2 diabetes mellitus: the EGO study analysis. Diabetologia 2009; 52: S59.
69. Thibaudeau K, Robitaille M, Wen S et al. CJC-1134-PC: an exendin-4 conjugate with extended pharmacodynamic profiles in rodents. Diabetes 2006; 55: A103.
70. Baggio LL, Huang Q, Cao X, Drucker DJ. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008; 134: 1137-1147.
71. Wang M, Kipnes M, Matheson S et al. Safety and pharmacodynamics of CJC-1134-PC, a novel GLP-1 receptor agonist, in patients with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blind, dose-escalation study. Diabetes 2007; 56: A133.
72. Wang M, Matheson S, Picard J, Pezzullo J, Ulich T. PC-DAC (TM): exendin-4 (CJC-1134-PC) significantly reduces HbA1c and body weight as an adjunct therapy to metformin: two randomized, double-blind, placebo-controlled, 12 week, phase II studies in patients with type 2 diabetes mellitus. Diabetes 2009; 58: A148.
73. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002; 19: 569-577.
74. Abbott CR, Monteiro M, Small CJ et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005; 1044: 127-131.
75. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273(4 Pt 1): G920-G927.
76. Madsbad S. Treatment of type 2 diabetes with incretin-based therapies. Lancet 2009; 373: 438-439.
77. Knudsen LB, Madsen LW, Andersen S et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 1473-1486.
78. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362: 774-777.
79. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006; 107: 2134-2142.
80. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
81. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
82. Girman CJ, Kou TD, Cai B et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010; 12: 766-771.
83. Bloomgren G, Dore D, Wenten M et al. Incidence and relative incidence of medical record confirmed acute pancreatitis: exenatide initiators compared to other antidiabetic drug initiators. Diabetes 2010; 59: A147-A148.
84. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 2009; 157: 1340-1351.
85. Shen L, Han J, Yushmanova I, Bruce S, Wilhelm K, Porter L. Cardiovascular safety of exenatide BID: an integrated-analysis from long-term controlled clinical trials in subjects with type 2 diabetes. Diabetologia 2009; 52: S298.
86. Gabber A, Matthews D, Holst J et al. The effect of diabetes duration on the response to liraglutide and glimepiride in type 2 diabetes. Diabetes 2010; 59: A197.
87. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
88. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.